QTc prolongation during antiviral therapy in two COVID-19 patients
- PMID: 32779770
- PMCID: PMC7405067
- DOI: 10.1111/jcpt.13183
QTc prolongation during antiviral therapy in two COVID-19 patients
Abstract
What is known and objective: Acquired long QT syndrome secondary to drug-induced QT prolongation and torsades de pointes has been reported for antiviral drugs. However, no studies have reported an association between corrected QT (QTc) prolongation and antiviral therapy in patients with novel coronavirus disease (COVID-19).
Case description: We present two cases from our institution in which patients with COVID-19 experienced QTc prolongation during treatment with antiviral therapy. Lopinavir/ritonavir, together with gender and drug-drug interactions, may have contributed to the induction of QTc prolongation in those patients.
What is new and conclusion: Co-administration of QT-prolonging medications and drugs interfering with the metabolism of those medications must be considered in patients with COVID-19. Careful analysis of electrocardiograms for QTc duration should be performed at baseline and during antiviral therapy to identify individuals at high risk of arrhythmias.
Keywords: COVID-19; QTc interval prolongation; drug interactions; lopinavir/ritonavir.
© 2020 John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):694-706. doi: 10.1002/pds.5234. Epub 2021 Apr 3. Pharmacoepidemiol Drug Saf. 2021. PMID: 33772933 Free PMC article.
-
Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.Medicine (Baltimore). 2021 Jul 16;100(28):e26538. doi: 10.1097/MD.0000000000026538. Medicine (Baltimore). 2021. PMID: 34260531 Free PMC article.
-
Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.Ir J Med Sci. 2021 Feb;190(1):403-409. doi: 10.1007/s11845-020-02291-7. Epub 2020 Jul 6. Ir J Med Sci. 2021. PMID: 32627127 Free PMC article. Review.
-
Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.Med J Malaysia. 2021 Mar;76(2):125-130. Med J Malaysia. 2021. PMID: 33742617
-
Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.Int J Antimicrob Agents. 2020 Oct;56(4):106142. doi: 10.1016/j.ijantimicag.2020.106142. Epub 2020 Aug 24. Int J Antimicrob Agents. 2020. PMID: 32853675 Free PMC article.
Cited by
-
Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19.Card Electrophysiol Clin. 2022 Mar;14(1):95-104. doi: 10.1016/j.ccep.2021.10.009. Epub 2021 Oct 30. Card Electrophysiol Clin. 2022. PMID: 35221089 Free PMC article. Review.
-
Safety profile of COVID-19 drugs in a real clinical setting.Eur J Clin Pharmacol. 2022 May;78(5):733-753. doi: 10.1007/s00228-021-03270-2. Epub 2022 Jan 28. Eur J Clin Pharmacol. 2022. PMID: 35088108 Free PMC article. Review.
References
-
- Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47(2):362‐367. - PubMed
-
- Singh M, Arora R, Jawad E. HIV protease inhibitors induced prolongation of the QT interval: electrophysiology and clinical implications. Am J Ther. 2010;17(6):e193‐e201. - PubMed
-
- Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365(9460):682‐686. - PubMed
-
- Stas P, Faes D, Noyens P. Conduction disorder and QT prolongation secondary to long‐term treatment with chloroquine. Int J Cardiol. 2008;127(2):e80‐e82. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources